RCI
SGMO

Ridgeback Capital Investments’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ridgeback Capital Investments’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,900,000
Closed -$40.3M – 4
2013
Q4 		$40.3M Buy
+2,900,000
New +$33.4M 50.91% 1

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Ridgeback Capital Investments's SGMO Position: Q1 2014 in Review

Ridgeback Capital Investments sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2014, closing a stake of 2,900,000 shares — an estimated $40.3M sold.

Ridgeback Capital Investments first reported a position in SGMO in Q4 2013 and held it in 1 quarter. The position peaked at $40.3M in Q4 2013. 145 funds tracked by Wall St. Rank hold SGMO as of Q1 2014.

  • Ridgeback Capital Investments reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2014 after selling out during the quarter.
  • Ridgeback Capital Investments sold 2,900,000 SANGAMO THERAPEUTICS INC shares in Q1 2014, an estimated $40.3M.
  • Ridgeback Capital Investments first reported a position in SANGAMO THERAPEUTICS INC in Q4 2013 and held it in 1 quarter.
  • Ridgeback Capital Investments's SANGAMO THERAPEUTICS INC position peaked at $40.3M in Q4 2013.
  • 145 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2014.

Based on Ridgeback Capital Investments's 13F filing for Q1 2014.